Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant for L-dopa Induced Dyskinesias in PD
NCT00582673Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mavoglurant in levodopa-induced dyskinesia (LID), sponsored by Novartis. Started Oct 2007; status: completed.
02
Drugs
mavoglurant
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT00582673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582673.